Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Global Cross-Pharmaceutical Clinical Trial Investigator Databank Established

Published: Friday, November 16, 2012
Last Updated: Friday, November 16, 2012
Bookmark and Share
Lilly and Merck are first to join Janssen in this pre-competitive initiative to increase efficiencies in clinical trials.

Janssen Research & Development, LLC (Janssen R&D) today announced the establishment of a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly and Company are the first two companies to join Janssen in this effort.

The new Investigator Databank, established as part of this novel industry collaboration, will serve as a one-stop repository where key information about clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records, is housed.   This will allow participating pharmaceutical companies to reduce  time-consuming and sometimes redundant administrative work involved in identifying appropriate clinical trial sites.

At the outset of every clinical trial, pharmaceutical companies initiate clinical trial site selection, prequalification and GCP training, which can be paperwork-heavy and time-consuming for trial sponsors and investigators alike.  By housing critical information about investigators and trial sites in one place, the databank will reduce time, cost and duplicative efforts, making it easier for companies to identify appropriate trial sites and investigators for future clinical trials. Investigator sites that have opted-in to data sharing will have their relevant information accessible to pharmaceutical companies participating in the collaboration. This databank will not include any patient data.

“The current clinical trial environment is inefficient, costly and unsustainable.  The  Investigator Databank can help expedite the process to achieve our most important goal – to deliver high-quality, effective novel medicines to the patients who  are waiting for them,” said Andreas Koester, MD, PhD, Head, Clinical Trial Innovation/External Alliances, Janssen Research & Development.  “We are enthusiastic about working with other industry leaders to collectively apply our expertise, capabilities and shared passion for advancing science and improving lives.”

Earlier this year, Janssen joined nine other companies to launch TransCelerate BioPharma Inc. ("TransCelerate"), the largest initiative of its kind, which aims to identify and overcome common drug development challenges in order to improve the quality of clinical studies and to bring new medicines to patients faster.  The initiative identified the centralization of site prequalification and training as one of five key projects, and the Janssen-led Investigator Databank project will serve as a foundation for the TransCelerate initiative.

“Industry collaboration, including pre-competitive data sharing, is critical to ensuring continued progress to improve industry-wide clinical trial practices,” said newly appointed CEO of TransCelerate BioPharma, Garry Neil, MD, Partner at Apple Tree Partners and formerly Corporate Vice President, Science & Technology, Johnson & Johnson. “This work is aligned with TransCelerate’s initial focus on clinical study execution and we encourage participation from our founding TransCelerate companies to solve industry-wide challenges in a collaborative environment.”

Member companies of TransCelerate who wish to join the Investigator Databank will automatically qualify for participation. It is anticipated that the Investigator Databank will be operational by the end of the year and incorporated into one of the priority projects within TransCelerate by mid-2013.

The Investigator Databank will be hosted by, an independent, third party with expertise in clinical trial information technology and investigator community management.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Johnson & Johnson Expects Lucrative Return on Drug Pipeline
Following the recent announcement of a number of collaborations and upcoming projects, the company hope their pharmaceutical business will continue to grow.
Thursday, May 21, 2015
J&J Announces Formation of Ebola Vaccine Development Consortia
Consortia funded through the IMI Ebola+ programme supported by the European Commission.
Friday, January 23, 2015
Johnson & Johnson Announces Major Commitment of Up to $200 Million
Commitment to speed Ebola vaccine development and significantly expand production.
Friday, October 31, 2014
Johnson & Johnson to Speed Ebola Vaccine Development, Significantly Expand Production
Company has committed up to $200M to vaccine program in development at its Janssen Pharmaceutical Companies.
Wednesday, October 22, 2014
Johnson & Johnson Announces Agreement to Acquire Alios BioPharma
Acquisition strengthens existing pipeline in viral diseases.
Wednesday, October 08, 2014
Johnson & Johnson, Dana-Farber Announce Immuno-Oncology Lung Cancer Collaboration
Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc. announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute.
Thursday, June 26, 2014
Johnson & Johnson to Acquire Aragon Pharmaceuticals, Inc.
Late-stage prostate cancer treatment strengthens oncology pipeline.
Thursday, June 20, 2013
J&JPRD Joins the Simcyp Consortium and Licenses the Simcyp Simulator
J&JPRD is now providing access to the Simcyp Population-based ADME Simulator and Paediatric module to its global network of research & development teams.
Wednesday, May 28, 2008
Johnson & Johnson Pharmaceutical Research & Development to Expand new Facility
The expanded facilities in Spring House, Pa., will house drug-development research into biomarkers, structural biology and pharmacogenomics.
Monday, April 23, 2007
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos